Results 171 to 180 of about 267,693 (315)

No difference in patient-reported outcome measures between private and public hospitals in the Netherlands: a cross-sectional analysis based on 170,150 hip and knee arthroplasties from the Dutch Arthroplasty Register. [PDF]

Acta Orthop
Vink MC, Bos P, Van Dooren BJ, Peters RM, Van Steenbergen LN, De Visser E, Brinkman JM, Schreurs BW, Zijlstra WP.   +8 more
europepmc   +1 more source

Genomic Insights Into Risperidone Treatment Outcomes in Children and Adolescents: Experience From a Psychiatric Hospital Serving Rural Youth

Clinical Pharmacology &Therapeutics, EarlyView.
Risperidone is a commonly used antipsychotic for treating psychiatric illness in children and adolescents. There is a large variability in risperidone response and discontinuation rates remain high. Pharmacogenomics offers the opportunity to improve risperidone outcomes, yet studies in pediatric populations are limited.
Jack W. Staples, Shayna R. Killam, Karen E. Brown, Rachel Dalton, Elizabeth Sather, Qiang Chen, Joshua Loveland, Corbin Schwanke, Abdallah F. Elias, Kristin L. Bigos, Erica L. Woodahl   +10 more
wiley   +1 more source

SA Private Hospitals

Point file of private hospitals in South Australia. The Australian Institute of Health and Welfare defines private hospitals as privately (non-government) owned and operated institutions catering for patients who are treated by a doctor of their own ...

core  

Patient-reported quality of primary care and facility endorsement in Addis Ababa. [PDF]

BMC Health Serv Res
Shamebo D, Mebratie AD, Arsenault C.
europepmc   +1 more source

Reducing Exposure Before Birth: An Interrupted Time Series Study of Prenatal Exposure to Fetotoxic Medications Under Risk Management Plans in Canada

Clinical Pharmacology &Therapeutics, EarlyView.
Canada's 2009 risk management plan (RMP) framework has not been evaluated for prenatal exposure impact. Conversely, widely used drugs such as nonsteroidal anti‐inflammatory drugs (NSAIDs) lack RMPs. We assessed first‐trimester exposure to RMP‐regulated medications following regulatory interventions and to NSAIDs following safety publications.
Nahiyan Saiyara Khan, Odile Sheehy, Lisiane Freitas Leal, Vanina Tchuente, Anick Bérard   +4 more
wiley   +1 more source

Essential lipid autacoids rewire mitochondrial energy efficiency in metabolic dysfunction‐associated fatty liver disease

Hepatology, EarlyView., 2022
Increased liver content of DHA‐derived small lipid autacoids (i.e resolvin D1 and maresin 1) associates with enhanced mitochondrial oxidative phosphorylation, fatty acid β‐oxidation and bioenergetic metabolic flux. These features provide hepatic protection from steatotic, pro‐inflammatory and fibrogenic insults.
Cristina López‐Vicario, David Sebastián, Mireia Casulleras, Marta Duran‐Güell, Roger Flores‐Costa, Ferran Aguilar, Juan José Lozano, Ingrid W. Zhang, Esther Titos, Jing X. Kang, Antonio Zorzano, Makoto Arita, Joan Clària   +12 more
wiley   +1 more source

Determinants of sustainable private hospitals

, 2019
This study took an integrated approach to determining sustainable private hospitals. What are the statistically significant factors for determining the sustainability of private hospitals in terms of (a) governance, (b) clinical care management, and (c ...
Montemayor, Conrado T., Tiu, Tomas S.
core  

Factors behind high caesarean section in Bangladesh: insight from a systematic literature review and meta-synthesis. [PDF]

BMJ Public Health
Ali M, Younger A, Votruba N, Hirst JE.
europepmc   +1 more source

Ruxolitinib Pharmacokinetics and Exposure–Toxicity Relationship in Hematologic Malignancies and Immune‐Mediated Diseases: A Prospective Observational Study

Clinical Pharmacology &Therapeutics, EarlyView.
Ruxolitinib pharmacokinetics (PK) has been characterized in clinical trials but remains poorly documented in real‐world practice. This project aimed to investigate ruxolitinib PK in routine clinical practice, identify factors driving its variability, and explore exposure–response relationships to assess the potential role of therapeutic drug monitoring.
Jérémie Tachet, Sara C. Meyer, Francesco Grandoni, Emmanuel Haefliger, Monika Nagy‐Hulliger, Jörg P. Halter, Jakob R. Passweg, David Haefliger, Carine Bardinet, Laurent A. Decosterd, Monia Guidi, François R. Girardin   +11 more
wiley   +1 more source

Health disparities in chronic liver disease

Hepatology, EarlyView., 2022
Abstract The syndemic of hazardous alcohol consumption, opioid use, and obesity has led to important changes in liver disease epidemiology that have exacerbated health disparities. Health disparities occur when plausibly avoidable health differences are experienced by socially disadvantaged populations.
Ani Kardashian, Marina Serper, Norah Terrault, Lauren D. Nephew   +3 more
wiley   +1 more source